Sumanta Kumar Pal, MD, a medical oncologist at the City of Hope Cancer Center, discussed the SWOG 1500 trial, the potential of cabozantinib for the treatment of papillary RCC, and the future of RCC care in an interview with Targeted Oncology,
Sara Karlovitch
Sara Karlovitch is an associate editor with Targeted Oncology. She received a duel degree in Journalism and Government and Politics from the University of Maryland.
Articles by Sara Karlovitch
Two newly-approved CAR T-cell agents are now being used to treat patients with relapsed/refractory non-Hodgkin lymphoma and multiple myeloma at University Hospitals in Ohio.
In an interview with Targeted Oncology, Komal Jhaveri, MD, FACP, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses HER2-positive metastatic breast cancer innovations, treatments, and upcoming studies.
The combination of durvalumab, tremelimumab, and chemotherapy showed statistically significant and clinically meaningful overall survival benefit compared to chemotherapy alone for the first-line treatment of patients with metastatic non-small cell lung cancer.
In an interview with Targeted Oncology, Bishop, discussed how CAR T cells have reshaped the treatment landscape, the future of their use, and their potential in solid tumors.
The National Comprehensive Cancer Network has added loncastuximab tesirine-lpyl to the NCCN Clinical Practice Guidelines in oncology for B-cell lymphomas.
In patients with multiple myeloma, the combination of motixafortide and granulocyte colony-stimulating factor achieved a 4.9-fold increase in hematopoietic stem-cell mobilization, and prepared most patients for autologous stem cell transplant, meeting both the primary and main secondary endpoints of the GENESIS Study.
The FDA has granted accelerated approval to pembrolizumab plus trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction cancer.
In an interview with Targeted Oncology, Mato, a hematologic oncologists and the director of the CLL Program at Memorial Sloan Kettering Cancer Center, discussed biomarker testing in CLL, and the future of BTK inhibitors in the CLL paradigm.
Masitinib in combination with docetaxel helps to prolong progression-free survival in metastatic castrate-resistant prostate cancer eligible to chemotherapy compared to placebo in combination with docetaxel, meeting the primary end point of the phase 3 AB12003 study.
Regular dose osimertinib demonstrated limited clinical activity in patients with non-small cell lung cancer harboring an EGFR exon 20 insertion who were treated in a phase 1/2 study.
In an interview with Targeted Oncology, Zeynep Eroglu, MD, discussed recent advances in melanoma treatment, exciting upcoming studies, and the evolving melanoma landscape.
In an interview with Targeted Oncology, Ursula A. Matulonis, MD, discusses results from further follow-up of patients with ovarian cancer treated in the ENGOT-OV16/NOVA.
The combination of oleclumab and osimertinib was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung cancer with an EGFR mutation after progression on an EGFR tyrosine kinase inhibitor.
In an interview with Targeted Oncology, Mark E. Johns, MD, discussed landmark esophageal cancer studies, newly approved treatments, and the future of the space.
The FDA’s Oncologic Drug Advisory Committee voted 5 to 4 against the continued accelerated approval of nivolumab for the treatment of patients with hepatocellular carcinoma who were previously treated with sorafenib.
The FDA’s Oncologic Drugs Advisory Committee voted 5 to 3 in favor of continued approval of pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.
Both KRAS and EGFR mutations have become increasingly important targets in non–small cell lung cancer. This is especially remarkable as KRAS was once considered an “untargetable mutation.”
The FDA has removed the clinical hold on the investigational new drug application of NL-201, a treatment for relapsed or refractory tumors, allowing a phase 1 clinical trial to begin.
The FDA has granted approval top loncastuximab tesirine for the treatment of relapsed or refractory diffuse large B-cell lymphoma, according to a press release from ADC Therapeutics.
The FDA has approved the VENTANA MMR RxDX panel, a device that determines if patients with advanced or recurrent endometrial cancer are eligible for treatment with dostarlimab-gxly monotherapy.
In an interview with Targeted Oncology following the FDA approval announcement for trilaciclib, Jared Weiss, MD, an assistant professor of medicine at the University of North Carolina Chapel Hill, discusses the use of trilaciclib in clinical practice and how it can improve patient quality-of-life by reducing the rate of neutropenia.
The Zangmeister Cancer Center in Columbus, Ohio has joined the American Oncology Network, LLC and the Sarah Cannon Research Institute as a strategic research site, according to a press release by AON.
Stuart J. Wong, MD, discussed the KEYNOTE-048 trial, advances in head and neck cancers, and current unmet needs in this patient population in an interview with Targeted Oncology.
In an interview with Targeted Oncology, Jennifer R. Brown, MD, PhD, discusses the chance of cardiovascular toxicities with BTK inhibitors and the safety of acalabrutinib.
Janssen Pharmaceutical Companies of Johnson & Johnson announced that they are not perusing the regulatory submission for apalutamide and abiraterone acetate as treatment of chemotherapy-naïve metastatic castration-resistant prostate cancer after the combination was not found to show significant benefit over the control combination of prednisone and abiraterone acetate.
In an interview with Targeted Oncology, Katelyn Handley, MD, discussed two studies on ovarian cancer subtypes and the use of a frailty index to determine patient outcomes before, during, and after ovarian cancer debulking surgery.
The FDA has granted priority review for 2 supplemental biologics license applications for enfortumab vedotin-ejfv for the treatment of a subset of patients with locally advanced or metastatic urothelial cancer.
GlaxoSmithKline plc has announced that they will stop enrolling patients in the phase 2 INDUCE-3 and INDUCE-4 trials while simultaneously ending the use of feladilimab, originally GSK3359609, for the treatment of PD-L1-positive recurrent locally advanced or metastatic head and neck squamous cell carcinoma after the recommendation of the Independent Data Monitoring Committee.
The FDA has approved nivolumab in combination with certain chemotherapies for the initial treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.